Close Menu

pancreatic cancer

In Genome Biology this week: loci linked to longitudinal pediatric bone accrual, role of complement cascade gene in pancreatic cancer metastases, and more.

Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.

Bluestar hopes to launch a pan-cancer, DNA methylation-based liquid biopsy assay as a laboratory-developed test out of an envisioned CLIA-certified lab in San Diego. 

The aggressive subtype, uncovered by a team of researchers in Germany, may also be susceptible to targeted therapy that blocks interferon signaling.

PanCAN has partnered with Tempus to provide panel genomic testing for every patient enrolled in the Precision Promise platform study.

Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.

The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.

The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.

Genomic and epigenomic data suggest it may be possible to target an FGFR fusion found in open chromatin in a subset of adenosquamous carcinoma of the pancreas tumors.

The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.